secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvation Bio Inc. (NUVB)
CIK:        0001811063
Form:       8-K
Filed at:   2022-05-09T23:59:59+00:00
Accession:  0001193125-22-145022
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvation Bio Q1 net loss $21.3M; pipeline focus on NUV-422, NUV-868, DDC
------------------------------------------------------------------------

- Net loss $21.3M ($0.10 per share) vs $20.4M ($0.12) in Q1 2021.
- Cash, cash equivalents and marketable securities $737.7M as of March 31, 2022.
- R&D expenses $20.7M (up $4.8M YoY); G&A $7.5M (up $2.9M YoY).
- On track to initiate Phase 1b combos and Phase 2 monotherapy for NUV-422 by end-2022; first patient dosed in NUV-868 Phase 1.
- Deprioritized early-stage NUV-569 and A2A programs to allocate resources to NUV-422, NUV-868, and DDC program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1811063/000119312522145022/0001193125-22-145022-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1811063/000119312522145022/d293509d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-145022

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer